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Emerging evidence has suggested that aldosterone has direct deleterious effects on the kidney inde-
pendently of its hemodynamic effects. However, the detailed mechanisms of these direct effects remain
to be elucidated. We have previously reported that camostat mesilate (CM), a synthetic serine protease
inhibitor, attenuated kidney injuries in Dahl salt-sensitive rats, remnant kidney rats, and unilateral
ureteral obstruction rats, suggesting that some serine proteases would be involved in the pathogenesis of
kidney injuries. The current study was conducted to investigate the roles of serine proteases and the
beneﬁcial effects of CM in aldosterone-related kidney injuries. We observed a serine protease that was
activated by aldosterone/salt in rat kidney lysate, and identiﬁed it as plasmin with liquid
chromatography-tandem mass spectrometry. Plasmin increased pro-ﬁbrotic and inﬂammatory gene
expressions in rat renal ﬁbroblast cells. CM inhibited the protease activity of plasmin and suppressed cell
injury markers induced by plasmin in the ﬁbroblast cells. Furthermore, CM ameliorated glomerulo-
sclerosis and interstitial ﬁbrosis in the kidney of aldosterone/salt-treated rats. Our ﬁndings indicate that
plasmin has important roles in kidney injuries that are induced by aldosterone/salt, and that serine
protease inhibitor could provide a new strategy for the treatment of aldosterone-associated kidney
diseases in humans.
© 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological
Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Aldosterone maintains sodium homeostasis mainly through the
activation of epithelial sodium channel (ENaC) in the distal
nephron. Therefore it is considered as a hormone to increase blood
pressure (1). However, mineralocorticoid receptor (MR) is
expressed in various cells other than renal tubular epithelial cells.
Furthermore, aldosterone has direct deleterious effects on theitamura).
rmacological Society.
g by Elsevier B.V. on behalf of Japa
d/4.0/).kidneys and other organs independently of its hemodynamic ef-
fects (2). The nonselective MR antagonist spironolactone and the
selective MR antagonist eplerenone have been shown to reduce
proteinuria in patients with kidney diseases independently of their
antihypertensive effects (3e6). Animal studies have revealed that
aldosterone directly provokes glomerular injuries and interstitial
ﬁbrosis through the induction of oxidative stress, inﬂammatory and
pro-ﬁbrotic cytokines, and apoptosis, as well as the activation of the
intrarenal renin-angiotensin system and other mechanisms (7e9).
However, the precise mechanisms of these effects need to be
further elucidated, and the role of serine proteases in aldosterone-
induced kidney injuries has not been evaluated.
Camostat mesilate (CM), a synthetic serine protease inhibitor, is
clinically applied for the treatment of chronic pancreatitis and
postoperative reﬂux esophagitis in Japan. We previously reportednese Pharmacological Society. This is an open access article under the CC BY-NC-ND
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injuries in Dahl salt-sensitive (DS) rats fed a high salt diet (10). In
addition, CM also alleviated glomerulosclerosis and interstitial
ﬁbrosis without changing blood pressure in remnant kidney model
and unilateral ureteral obstruction kidney model (11,12). Further-
more, we have recently reported that CMmitigated renal ﬁbrosis in
adenine-induced chronic kidney disease rats more than hydral-
azine even though blood pressure levels with both treatments were
similar (13,14). In those studies, CM exerted its renoprotective ef-
fects through the suppression of inﬂammatory and pro-ﬁbrotic
cytokine expression, reactive oxygen species (ROS) production
and transforming growth factor b (TGF-b) signaling. These results
suggest that some serine proteases might be involved in the pro-
gression of kidney injuries and that CM could provide beneﬁcial
effects by inhibiting the relevant proteases.
In the current study, we demonstrated that serine protease
plasmin was activated in an MR dependent manner within kidney
tissue of aldosterone/salt-treated rats. CM suppressed the protease
activity of plasmin and alleviated the kidney injuries that were
induced by aldosterone/salt.
2. Materials and methods
2.1. Animal study
All animal procedures were conducted in accordance with the
guidelines for the care and use of laboratory animals that have been
approved by Kumamoto University. Experiments were conducted
in male SpragueeDawley (SD) rats from Charles River Laboratories
(Wilmington, MA, USA). The rats underwent left uninephrectomy at
7 weeks old and were divided into one of the following groups at 9
weeks old:
Protocol 1: Effects of aldosterone and salt on serine protease
activities in the kidney. (1) Control (0.3% NaCl diet), (2) high salt
diet (8.0% NaCl diet), (3) aldosterone (0.75 mg/h), (4)
aldosterone þ high salt diet (A þ S).
Protocol 2: The effects of eplerenone on kidney injuries induced
by aldosterone and salt. (1) Control, (2) aldosterone þ high salt
diet, (3) aldosterone þ high salt diet þ eplerenone (0.125% diet).
Protocol 3: The effects of camostat mesilate on kidney injuries
induced by aldosterone and salt. (1) Control, (2)
aldosterone þ high salt diet, (3) aldosterone þ high salt diet þ CM
(0.1% diet).
Aldosterone (SigmaeAldrich Co., St. Louis, MO, USA) was dis-
solved in dimethyl sulfoxide (DMSO) and saline, and then infused
subcutaneously at the dorsum of the neck using an osmotic mini-
pump (model 2004; Alza Corp., Palo Alto, CA, USA). Systolic blood
pressure (SBP) was measured under awake conditions using a tail
cuff method (MK-2000; Muromachi Kikai Co., Ltd., Osaka, Japan).
Twenty-four hour urine collections were performed in metabolic
cages, and urinary protein was measured by a commercial labora-
tory (SRL, Tokyo, Japan). After 4 weeks, the rats were sacriﬁced
under anesthetic conditions. After blood samples had been
collected from the inferior vena cava, the right kidneys were
weighed and sliced through the short axis to obtain approximately
3 mm thick sections. The sections were then treated as described
below. Serum creatinine and albumin levels were measured by SRL.
2.2. Zymography
A slice of kidney was homogenized with a polytron in ice-cold
Tissue Protein Extraction Reagent (T-PER, Thermo scientiﬁc, Rock-
ford, IL, USA) without a protease inhibitor cocktail. Aliquots of pro-
teins (90 mg) were subjected to serine protease speciﬁc zymography
(Cosmo Bio Co., Ltd, Tokyo, Japan) following the manufacturer'sinstructions. Double-layer ﬂuorescent zymography (DLF-Zymog-
raphy) was carried out as described previously (15). Brieﬂy, aliquots
of proteins (90 mg) were subjected to SDS-PAGE (sodium dodecyl
sulfateepolyacrylamide gel electrophoresis) in non-reduced condi-
tion. After washing with 2.5% TritonX-100 for 30 min followed by
immersion in 50mMTriseHCl (pH 8.2), the gel was incubatedwith a
cellulose acetate membrane treated with 100 mM TriseHCl and
0.2 mM N-t-Boc-Gln-Ala-Arg-7-amido-4-methylcoumarin (QAR-
MCA, the substrate for a serine protease such as trypsin), which had
been purchased from Peptide Institute (Osaka, Japan). After incuba-
tion at 37 C for 1 h, the 7-amino-4-methylcoumarin released by the
cleavage at the C-terminal of argininewith the serine proteases were
visualized on an ultraviolet transilluminator at wave length of
365 nm. To conﬁrm the inhibitory effect of CM on the serine pro-
teases in the kidney homogenate, we added CM into the substrate
solution in ﬁnal concentrations of 0.5 and 5.0 mM.
2.3. Identiﬁcation of serine protease
Kidney homogenates were precipitated in ammonium sulfate
solution in 0e30%, 30e50%, 50e70% or 70e100% concentrations.
Each fraction was dissolved in 50 mM TriseHCl pH 7.6 with 0.1%
CHAPS (Buffer A) and desalted in dialysis. Thereafter, it was sub-
jected to DLF-Zymography in non-reduced condition. The fraction
of 30e50% ammonium sulfate for which we observed the strongest
activity of the target serine protease was demonstrated into an ion
exchange chromatography column (Hi trap Q; GE Healthcare Bio
Sciences, Piscataway, NJ, USA), which was pre-equilibrated with
Buffer A using an AKTA prime chromatography system (GE
Healthcare Bio Sciences). After being washed with Buffer A, the
columnwas eluted with a linear gradient of 0e1.0 M NaCl in Buffer
A. After ion exchange chromatography, each fraction was also
subjected to DLF-Zymography and silver staining (Wako Pure
Chemical Industries., Ltd, Osaka, Japan). For fractions that showed
relatively higher activity of target serine protease and relatively
fewer contaminating proteins with silver staining, we applied two
sets of SDS-PAGE followed by DLF-Zymography and Deep Purple
Total Protein Stain (GE Healthcare Bio Sciences). Stained proteins
corresponding to target protease activity in DLF-Zymography were
analyzed with a liquid chromatography-tandem mass spectrom-
etry (LC-MS/MS) system.
2.4. Real-time PCR
A piece of kidney was placed in RNA later (Sigma Chemical Co.)
at 4 C overnight. Total RNA was extracted with an ST Total RNA
Isolation System (Promega, Fitchburg, WI, USA). One microgram of
total RNA was ﬁrst transcribed with a Prime Script RT Reagent Kit
(Takara Bio Inc., Shiga, Japan). TaqMan probes for rat collagen I,
collagen III, TGF-b, connective tissue growth factor (CTGF), B7-1,
monocyte chemoattractant protein-1 (MCP-1), TNF-a, tissue-type
plasminogen activator (tPA), urokinase-type plasminogen acti-
vator (uPA), plasminogen activator inhibitor-1 (PAI-1) and protease
activated receptor-1 (PAR-1) and GAPDH were all purchased from
Applied Biosystems (Foster City, CA, USA). Real-time PCR was per-
formedwith the Light Cycler 480 Sequence Detector System (Roche
Diagnostics, Mannheim, Germany). The results were analyzed sta-
tistically based on the DCt value (Ctgene of interest CtGAPDH). Relative
gene expressions were obtained using the DDCt method
(Ctsample  Ctcalibrator).
2.5. Chromogenic assay of plasmin activity in the kidney tissue
In protocol 3, renal plasmin activities were measured using
Chromozym PL (Tosyl-Gly-Pro-Lys-4-nitroanilide acetate,
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as described previously (16). This substance is cleaved by plasmin
into a residual peptide and 4-nitroaniline that can be detected
spectrophotometrically.
2.6. Kidney histopathology
In protocol 3, the kidneys were ﬁxed with 4% paraformaldehyde
and embedded in parafﬁn. Sections (4 mm thick) were stained with
Periodic acid-Schiff (PAS) and Azan Mallory and were examined
under a light microscope. The glomerulosclerosis score was calcu-
lated in a blind manner from approximately 50 to 100 glomeruli of
each rat as described previously (17).
2.7. Immunoblotting
A slice of kidneywas homogenized with a polytron in ice-cold T-
PER with a protease inhibitor cocktail. Aliquots of 30 mg renal
proteins were subjected to SDS-PAGE in reduced condition and
were immunoblotted with anti-Wilms' tumor-1 (WT-1) and
GAPDH (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA).
2.8. In vitro study
2.8.1. The effect of camostat on plasmin activity
QAR-MCA (ﬁnal concentration: 1 mmol/L in 96-well microliter
plates) was incubated with 20 mg/mL plasmin in the presence of
different concentrations of CM (0e5 mM) in 50 mM TriseHCl (pH
8.2). The degree of substrate hydrolysis was measured by using a
ﬂuorescent microplate reader (Ultra Evolution; Tecan, Zurich,
Switzerland) at an excitation of 360 nm and an emission of 465 nm.
The residual activity of plasmin (velocity of inhibited enzyme re-
action/velocity of uninhibited enzyme reaction) was expressed
versus the CM concentration.
2.8.2. Renal ﬁbroblast cells
A renal ﬁbroblast cell line (NRK-49F) was purchased from Hu-
man Science Research Resources Bank (HSRRB, Osaka, Japan). Cells
were maintained in advanced DMEM supplemented with 5% fetal
calf serum (Invitrogen, Carlsbad, CA, USA). The cells were seeded in
6-well culture plates and grown to subconﬂuence in complete
medium. Subsequently, the culture medium was replaced with
serum-free medium for 24 h to render the cells quiescent. Human
plasmin (Sigma chemical Co.) was dissolved in serum free medium
and added to the culture medium at a ﬁnal concentration of 20 mg/
mL, as described previously (18) in the presence of CM (0e5 mM).
After cells were incubated for another 72 h, Total RNAwas extracted
and real-time PCR was performed as described above.
2.8.3. Statistical analysis
Data are expressed as mean ± standard deviation (SD). Com-
parisons were made using analysis of variance (ANOVA) followed
by the NewmaneKeuls method or the two-tailed, unpaired Stu-
dent's t-test. P < 0.05 was considered statistically signiﬁcant.
3. Results
3.1. Animal study protocol 1: effects of aldosterone and salt on the
serine protease activities in the kidney
In accordance with previous reports (19), only the A þ S group
developed hypertension and severe urinary protein excretion
(Fig. 1A and B). Correspondently, the mRNA expressions of collagen
type I, collagen type III, TGF-b1, TNF-a, and B7-1 were signiﬁcantly
increased in the A þ S group alone (Fig. 1C).3.2. Serine protease activities in the kidney homogenate
Serine protease speciﬁc zymography using kidney lysate
revealed an approximately 80-kDa band that was only activated in
the A þ S group (Fig. 2A). DLF-Zymography with QAR-MCA sub-
strate provided a similar result (Fig. 2B).3.3. Identiﬁcation of serine protease
Following the fractionation of kidney homogenate by ammo-
nium sulfate precipitation and ion-exchange chromatography, we
isolated two fractions of kidney lysate with relatively stronger ac-
tivity of the target serine protease and fewer contaminating pro-
teins (data not shown). Those fractions were then applied together
to two sets of SDS-PAGE, followed by DLF-Zymography and Deep
Purple Total Protein Stain (Fig. 2C). The stained band corresponding
to the target protease activity in DLF-Zymography was subjected to
the LC-MS/MS analysis and thereby identiﬁed as plasminogen/
plasmin.3.4. mRNA expression of tPA, uPA, PAI-1 and PAR-1
The gene expressions of tPA, uPA and PAI-1 were measured in
order to examine the mechanism by which plasminogen was
activated into plasmin within the renal tissue. tPA mRNA was
slightly but signiﬁcantly increased by aldosterone/salt, suggesting
that tPA plays roles in the activation of renal plasmin. PAI-1 mRNA
was dramatically increased by aldosterone/salt possibly to
compensate the overactivation of renal plasmin. mRNA expression
of PAR-1, which is one of plasmin receptors, was increased by
aldosterone/salt (Fig. 3B).3.5. Animal study protocol 2: the effects of eplerenone on
aldosterone/salt-induced kidney injuries and plasmin activity
Eplerenone attenuated the aldosterone/salt-induced hyperten-
sion, urinary protein excretion, and mRNA expressions of kidney
injury markers, as has also been reported previously (Table 1 and
Fig. 3A) (9). Eplerenone also signiﬁcantly suppressed the
aldosterone/salt-induced plasmin activity in the kidney (Fig. 3B),
indicating that mineralocorticoid receptor had an important role in
the activation of plasmin.3.6. In vitro study
3.6.1. Inhibition of proteolytic activity of plasmin by camostat
mesilate
CM inhibited the proteolytic activity of plasmin signiﬁcantly in
concentrations of 0.5 and 5 mM. Inhibitory rates of CM on plasmin
activity were 70.2 ± 5.1% and 91.2 ± 4.0% for concentrations of 0.5
and 5 mM respectively (Fig. 4A). Accordingly, the administration of
CM in DLF-zymography suppressed plasmin activity in the kidney
lysate (Fig. 4B).3.6.2. Camostat mesilate suppresses the plasmin-induced cytokines
expression in cultured renal ﬁbroblast cells
The mRNA expressions of pro-ﬁbrotic and inﬂammatory cyto-
kines (TGF-b1, CTGF, MCP-1, and TNF-a) were signiﬁcantly
increased by 20 mg/mL of plasmin, indicating that plasmin has
detrimental effects on NRK-49F cells. Those effects of plasminwere
signiﬁcantly ablated by CM (0.5 and 5 mM) (Fig. 4C).
Fig. 1. Effects of aldosterone and salt on SBP (A), urinary protein (B) and mRNA expressions of kidney injury markers (C) in uninephrectised aldosterone/salt-treated rats.
Aldosterone and high salt were administrated to 9-week-old uninephrectomized rats. (A) SBP was measured by tail-cuff method every second week. (B) Twenty-four hour urine
collections were made in metabolic cages and urinary protein concentrations were determined at each time point. (C) mRNA expressions of kidney injury markers were determined
by real-time PCR. The abundance of each mRNA was normalized by GAPDH. Values are expressed as fold increase over Control group and summarized in the bar graph. Cont,
control; Salt, salt-treated group; Ald, aldosterone-treated group; A þ S, aldosterone/salt-treated group; Col I and III, Collagen I and III. Data are expressed as mean ± SD (n ¼ 5).
yP < 0.01 vs. Control.
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aldosterone/salt-induced kidney injuries
3.7.1. Renal plasmin activity
Renal plasmin activity measured with a plasmin-speciﬁc sub-
strate Chromozym PL was signiﬁcantly upregulated in the A þ S
group and was substantially suppressed in the CM group, sug-
gesting that renal concentration of CM was adequate to inhibit
plasmin (Fig. 5A).
3.7.2. Body weight, organ weight and blood pressure
Body weights in the A þ S and CM groups were smaller than
those in the Control group (Table 2). The administration of aldo-
sterone/salt signiﬁcantly increased blood pressure immediately
after 1 week, and blood pressure continued to increase until week
4. Treatment with CM signiﬁcantly attenuated hypertension at
week 4 (Fig. 5B). The ratio of right kidney weight to body weight
was increased by aldosterone/salt, which was signiﬁcantly sup-
pressed by CM (Table 2).
3.7.3. Blood and urine parameters
In the A þ S group, serum creatinine increased and serum al-
bumin decreased, reﬂecting severe kidney injuries. However,
concomitant administration of CM inhibited these changes
(Table 2). Urinary protein levels dramatically increased in the A þ S
group, however this changewas suppressed by CM as early as week
2 (Fig. 5C). CM exerted renoprotective effects earlier than its anti-
hypertensive effect, indicating that plasmin in kidney tissue would
provoke kidney injuries independently of blood pressure.3.7.4. Kidney histopathology
Light microscopic examination revealed severe glomerular hy-
pertrophy, glomerular sclerosis, and tubulointerstitial ﬁbrosis in
the Aþ S group; eachwas signiﬁcantly alleviated by treatment with
CM (Fig. 6A). The protein expression of WT-1 was decreased in the
A þ S group and was strikingly recovered in the CM group. These
results indicate that CM substantially mitigated podocyte injuries
caused by aldosterone/salt.
3.7.5. mRNA expression of kidney injury markers
mRNA levels of collagen type I, collagen type III, TGF-b1, B7-1,
and MCP-1 were all signiﬁcantly increased in A þ S group, as
compared with those in the Control group. Treatment with CM
apparently suppressed all of these kidney injury markers (Fig. 6B).
4. Discussion
The current investigation was designed to identify serine pro-
tease(s) associated with kidney injuries that had been induced by
aldosterone/salt. We further sought to conﬁrm the beneﬁcial effects
of CM on these kidney injuries. We found a serine protease that is
substantially activated in the kidneys of aldosterone/salt-treated
rats. The column puriﬁcation and LC-MS/MS analysis identiﬁed
the serine protease as plasminogen/plasmin. Plasmin induced
mRNA expression of pro-ﬁbrotic and inﬂammatory genes in
cultured renal ﬁbroblasts, however CM suppressed these in-
ductions. Moreover, the administration of CM signiﬁcantly allevi-
ated urinary protein excretion, glomerular sclerosis and
tubulointerstitial ﬁbrosis. These effects of CMwere accompanied by
Fig. 2. Effects of aldosterone/salt on the serine protease activities in the kidney homogenate. (A) Serine protease speciﬁc zymography and (B) DLF-Zymography with QAR-MCA
substrate displayed a serine protease at approximately 80 kDa that was highly activated in the kidney homogenate of A þ S group. (C) Following the puriﬁcation of kidney ho-
mogenate by ammonium sulfate precipitation and ion-exchange chromatography, the fractions that showed relatively higher activity of target serine protease and fewer
contaminating proteins were applied to two sets of SDS-PAGE followed by DLF-Zymography (Left) and Deep Purple Total Protein Stain (Right). Ninety microgram of kidney ho-
mogenate was applied to each zymography in non-reduced condition. (D) mRNA expressions of tPA, uPA, PAI-1 and PAR-1 were determined by real-time PCR. Abundance of each
mRNA was normalized for GAPDH and values are expressed as fold increase over Cont. Cont, control; Salt, salt-treated group; Ald, aldosterone-treated group; A þ S, aldosterone/
salt-treated group. Data are expressed as mean ± SD (n ¼ 5). yP < 0.01 vs. Control.
Fig. 3. Effects of eplerenone on the serine protease activity and kidney injury markers in uninephrectised aldosterone/salt rats. Eplerenone (0.125% diet) was administrated to
9-week-old uninephrectomized rats treated with aldosterone/salt. (A) mRNA expressions of kidney injury markers were determined by real-time PCR. The abundance of each mRNA
was normalized by GAPDH. Values are expressed as fold increase over Control group and summarized in the bar graph. Data are expressed as mean ± SD (n ¼ 8). yP < 0.01 vs.
Control; *P < 0.01 vs. A þ S. (B) The effect of eplerenone on the protease activity of plasmin in the kidney. Kidney homogenates (90 mg) of each group were applied to DLF-
Zymography with QAR-MCA substrate.
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aldosterone/salt-treated rats.
The plasminogen-plasmin system plays pivotal roles in the
ﬁbrinolytic system, converting ﬁbrin to ﬁbrin degradation productsin the intravascular area. The pro-enzyme plasminogen is synthe-
sized in the liver and converted to its active form plasmin by
cleavage with tPA and uPA (20,21). Both tPA and uPA are inhibited
by plasminogen activator inhibitors (PAIs), and PAI-1 is their
Table 1
Effects of eplerenone on (patho)physiological parameters in uninephrectised aldo-
sterone/salt rats.
Cont A þ S Eple
BW (g) 410 ± 11 393 ± 36 412 ± 27
rt Kidney wt (mg/g BW) 4.6 ± 0.2 9.0 ± 0.9y 6.0 ± 0.7yx
SBP (mmHg) 110 ± 5 174 ± 11y 140 ± 10yx
U-TP (mg/day) 15 ± 7 501 ± 86 52 ± 62*
Alb (g/dL) 3.8 ± 0.1 3.2 ± 0.2y 3.7 ± 0.3x
Cr (mg/dL) 0.41 ± 0.02 0.52 ± 0.04y 0.39 ± 0.02*
Cont, control; A þ S, aldosterone/salt-treated group; Eple, aldosterone/salt and
concomitant eplerenone-treated group; BW, body weight at week 4; SBP, systolic
blood pressure at week 4; U-TP, urinary protein excretion at week 4; Alb, serum
albumin level; Cr, serum creatinine level. Data are expressed as mean ± SD (n ¼ 8).
yP < 0.01 vs. Cont, xP < 0.05 vs. A þ S, *P < 0.01 vs. A þ S.
Y. Kakizoe et al. / Journal of Pharmacological Sciences 132 (2016) 145e153150dominant physiological inhibitor (22). In the kidney, tPA is the
major glomerular plasminogen activator, while uPA is prominently
expressed in the renal tubulointerstitium (23). Plasmin in urine has
been reported to be associated with sodium retention in the
nephrotic syndrome. Plasminogen ﬁltered through damaged
glomeruli is converted to plasmin by uPA within the renal tubules,
and plasmin activates ENaC with the proteolytic cleavage of g
subunit leading to edema and hypertension (24). As we reported
that CM inhibited the proteolytic cleavage of gENaC in vivo, CM
might suppress hypertension via the inhibition of ENaC and miti-
gate the kidney injuries in the current experiment (25). However,
CM reduced urinary protein excretion (beginning at week 2) before
having an evident anti-hypertensive effect (which was observed atFig. 4. Effects of camostat mesilate on the plasmin activity and the expression of kidne
(ﬁnal concentration: 1 mmol/L) was incubated with 20 mg/mL plasmin in the presence of
substrate hydrolysis was measured by using a ﬂuorescent microplate reader. The residual ac
reaction) was shown versus CM concentration. Data are expressed as mean ± SD (n ¼ 4). *P
DLF-zymography substrate solution. CM suppressed plasmin activity in the dose-dependent
with 20 mg/mL plasmin and CM (0e5.0 mM, ﬁnal concentration) for 72 h. CM suppressed th
expressions of kidney injury markers were determined by real-time PCR. The abundance o
Control group and summarized in the bar graph. Data are expressed as mean ± SD (n ¼ 6)week 4), suggesting that plasmin activated by aldosterone/salt
within the kidney tissue is highly associated with blood pressure-
independent detrimental effects of aldosterone.
Although the role of plasminogen-plasmin system in kidney
injury has been reported in various studies, it remains a matter of
debate. A study of crescentic glomerulonephritis demonstrated that
endogenous plasmin that was activated by exogenous tPA inhibited
glomerular ﬁbrin accumulation and glomerular damage (26). In
contrast, it was also found that plasmin, which was attached to
glomerulus through nephritis-associated plasmin receptor (NAPlr),
could initiate glomerular injuries in human acute post-
streptococcal glomerulonephritis (27). These conﬂicting reports
suggest that plasmin could have biphasic effects on the progression
of kidney injuries, depending on disease states. The pathogenic
roles of plasmin in the development of interstitial ﬁbrosis also
remain to be elucidated. Plasmin has been shown to directly
degrade extracellular matrix proteins, such as ﬁbronectin, laminin,
and proteoglycan (28). Furthermore, plasmin has been shown to
activate matrix metalloproteinases, which also alleviate interstitial
collagen accumulation (29). Therefore, plasmin had been consid-
ered to be anti-ﬁbrotic protease in some organs (30e32). However,
recent studies have demonstrated that plasmin exacerbates renal
ﬁbrosis in unilateral ureteral obstruction mice by activating TGF-b1
and stimulating PAR-1 and its downstream molecule ERK-1/2
(18,33). In addition to its pro-ﬁbrotic effects, plasmin contributes
to inﬂammation by provoking cytokine productions (such as TNF-a
and MCP-1) and inﬂammatory cell inﬁltrations (34,35). Further-
more, plasmin produces reactive oxygen species (ROS) (35). In the
current study, plasmin might have caused severe kidney injuries
through the induction of these molecules, which were recovered byy injury markers induced by plasmin in cultured renal ﬁbroblast cell. (A) QAR-MCA
different concentrations of CM (0e5 mM) in 50 mM TriseHCl (pH 8.2). The degree of
tivity of plasmin (velocity of inhibited enzyme reaction/velocity of uninhibited enzyme
< 0.01 vs. Vehicle. (B) Vehicle, 0.5 mM and 5.0 mM of CM (ﬁnal concentration) were into
manner. (C) After serum deprivation, the cultured renal ﬁbroblast cells were incubated
e mRNA expression of kidney injury markers induced by plasmin from 0.5 mM. mRNA
f each mRNA was normalized for GAPDH. Values are expressed as fold increase over
. yP < 0.01 vs. Control, *P < 0.01 vs. PL.
Fig. 5. Effects of camostat mesilate on renal plasmin activity (A), SBP (B) and urinary protein (C) in uninephrectised aldosterone/salt rats. CM (0.1% diet) was administrated to
9-week-old uninephrectomized rats treated with aldosterone/salt. (A) Renal plasmin activities in each group were measured using Chromozym PL that is speciﬁcally cleaved by
plasmin. Relative plasmin activities were expressed as fold increase over Control group and summarized in the bar graph. (B) SBP was measured by tail-cuff method weekly. (C)
Twenty-four hour urine collections were made in metabolic cages and urinary protein concentrations were determined at each time point. Cont, control; A þ S, aldosterone/salt-
treated group; CM, aldosterone/salt and concomitant CM-treated group. Data are expressed as mean ± SD (n ¼ 8). #P < 0.05 vs. Cont, yP < 0.01 vs. Cont, xP < 0.05 vs. A þ S, *P < 0.01
vs. A þ S.
Table 2
Effects of camostat mesilate on (patho)physiological parameters in uninephrectised
aldosterone/salt rats.
Cont A þ S CM
BW (g) 438 ± 23 375 ± 22y 366 ± 17y
rt Kidney wt (mg/g BW) 4.8 ± 0.6 9.9 ± 1.3y 7.8 ± 0.5y§
Alb (g/dL) 3.8 ± 0.1 3.2 ± 0.4y 3.6 ± 0.2§
Cr (mg/dL) 0.38 ± 0.04 0.54 ± 0.06y 0.40 ± 0.09*
Cont, control; A þ S, aldosterone/salt-treated group; CM, aldosterone/salt and
concomitant camostat-treated group; BW, body weight at week 4; Alb, serum al-
bumin level; Cr, serum creatinine level. Data are expressed as mean ± SD (n ¼ 8).
yP < 0.01 vs. Cont, xP < 0.05 vs. A þ S, *P < 0.01 vs. A þ S.
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reported that CM prevented pro-ﬁbrotic and inﬂammatory mole-
cules and oxidative stress in other experimental rat models of
kidney disease (10e14).
To the best of our knowledge, there has been no report to
elucidate the relationship between aldosterone, MR and PAR-1 in
the progression of kidney diseases. In this study, aldosterone/salt
increased plasmin activity as well as mRNA expression of PAR-1 in
the kidney, indicating that both effects synergistically exacerbated
kidney damages. As CM suppressed plasmin activity in the kidney,
the following inhibition of PAR-1 activation might have attenuated
aldosterone-induced kidney injuries. Correspondingly, mRNA of
PAR-1 was detectable in NRK-49F cells (data not shown) and CM
prevented pro-ﬁbrotic and inﬂammatory cytokine inductions
caused by plasmin.
We were not able to clearly demonstrate the mechanism by
which plasmin was activated in the kidney tissue of aldosterone/
salt-treated rats. Because mRNA expression of plasminogen was
not detectable in the kidney (18), and because we could neverobserve plasmin activity in the plasma from control or aldoste-
rone/salt rats in DLF-Zymography (data not shown), circulating
plasminogen could be trapped in the kidney tissue and activated
locally via the interaction of aldosterone and MR, which was
suppressed by eplerenone. Although mRNA expression of tPA in
the kidney was slightly upregulated by aldosterone/salt, it is
difﬁcult to conclude that tPA was the dominant plasminogen
activator in this model because upstream protease activity is more
important than its gene expression in the serine protease cascade.
In this study, we did not elucidate the protease activities of each
plasminogen activator in the kidney. Additional studies are
necessary to shed light on the detailed mechanism of renal
plasmin activation.
In the present study, we used two different substrates for
zymography to identify a serine protease plasmin that is activated
by aldosterone/salt in the kidney. However, we cannot exclude
the possibility that kidney injuries caused by aldosterone/salt
involve other serine proteases that are undetectable with our
methods. Other serine proteases such as elastase, cathepsin G,
neutrophil serine protease and coagulation factor Xa have been
known to induce kidney diseases (11,12,36,37). Although we did
not evaluate the inhibitory effects of CM on these proteases, there
were possibilities that CM inhibited kidney injuries via the sup-
pression of these protease cascades in addition to plasmin.
Further studies, particularly using plasminogen deﬁcient mice,
are deﬁnitely required to address the role of plasmin in kidney
injuries.
The results of the current study suggest that serine protease
plasmin induced by aldosterone/salt would cause kidney injuries.
Serine protease inhibitors, such as CM, could provide a new strat-
egy for the treatment of aldosterone-associated kidney injuries in
humans.
Fig. 6. Effects of camostat mesilate on kidney histopathology (A), WT-1 (B) and kidney injury markers (C) in uninephrectised aldosterone/salt rats. (A) Representative
photomicrographs (400) of periodic acid-Schiff (PAS) and Azan Mallory (Azan) stained kidney sections. The glomerulosclerosis score was calculated from approximately 50 to 100
glomeruli of each rat. (B) Protein expressions of WT-1 in the kidney were evaluated by Western blot analysis. The densitometry values were normalized for GAPDH and were
expressed as fold increase over Control group. (C) mRNA expressions of kidney injury markers were determined by real-time PCR. The abundance of each mRNA was normalized by
GAPDH. Values are expressed as fold increase over Control group and summarized in the bar graph. Cont, control; A þ S, aldosterone/salt-treated group; CM, aldosterone/salt and
concomitant CM-treated group. Data are expressed as mean ± SD (n ¼ 8). #P < 0.05 vs. Cont; yP < 0.01 vs. Cont, xP < 0.05 vs. A þ S, *P < 0.01 vs. A þ S.
Y. Kakizoe et al. / Journal of Pharmacological Sciences 132 (2016) 145e153152Conﬂict of interest
The authors indicated no potential conﬂicts of interest.
Acknowledgments
The authors thank Ms. Noriko Nakagawa and Ms. Naoko Hirano
(Graduate School of Medical Sciences, Kumamoto University) for
their expertise in histopathology. This work was supported by the
Grants-in-Aid for Scientiﬁc Research from the Ministry of Educa-
tion, Science and Culture in Japan (23790948 to Y. Kakizoe), The Salt
Science Research Foundation (1532 to Y. Kakizoe).
References
(1) Masilamani S, Kim GH, Mitchell C, Wade JB, Knepper MA. Aldosterone-
mediated regulation of ENaC alpha, beta, and gamma subunit proteins in rat
kidney. J Clin Invest. 1999;104(7):R19eR23.
(2) Funder JW. Aldosterone, mineralocorticoid receptors and vascular inﬂam-
mation. Mol Cell Endocrinol. 2004;217(1e2):263e269.
(3) Chrysostomou A, Becker G. Spironolactone in addition to ACE inhibition to
reduce proteinuria in patients with chronic renal disease. N Engl J Med.
2001;345(12):925e926.
(4) Rachmani R, Slavachevsky I, Amit M, Levi Z, Kedar Y, Berla M, et al. The effect
of spironolactone, cilazapril and their combination on albuminuria in patients
with hypertension and diabetic nephropathy is independent of blood pressure
reduction: a randomized controlled study. Diabet Med. 2004;21(5):471e475.
(5) Sato A, Hayashi K, Naruse M, Saruta T. Effectiveness of aldosterone blockade in
patients with diabetic nephropathy. Hypertension. 2003;41(1):64e68.
(6) Kiyomoto H, Raﬁq K, Mostofa M, Nishiyama A. Possible underlying mecha-
nisms responsible for aldosterone and mineralocorticoid receptor-dependent
renal injury. J Pharmacol Sci. 2008;108(4):399e405.(7) Fan YY, Baba R, Nagai Y, Miyatake A, Hosomi N, Kimura S, et al. Augmentation
of intrarenal angiotensin II levels in uninephrectomized aldosterone/salt-
treated hypertensive rats; renoprotective effects of an ultrahigh dose of
olmesartan. Hypertens Res. 2006;29(3):169e178.
(8) Nishiyama A, Abe Y. Molecular mechanisms and therapeutic strategies of
chronic renal injury: renoprotective effects of aldosterone blockade.
J Pharmacol Sci. 2006;100(1):9e16.
(9) Shibata S, Nagase M, Yoshida S, Kawachi H, Fujita T. Podocyte as the target for
aldosterone: roles of oxidative stress and Sgk1. Hypertension. 2007;49(2):
355e364.
(10) Maekawa A, Kakizoe Y, Miyoshi T, Wakida N, Ko T, Shiraishi N, et al. Camostat
mesilate inhibits prostasin activity and reduces blood pressure and renal
injury in salt-sensitive hypertension. J Hypertens. 2009;27(1):181e189.
(11) Hayata M, Kakizoe Y, Uchimura K, Morinaga J, Yamazoe R, Mizumoto T, et al.
Effect of a serine protease inhibitor on the progression of chronic renal failure.
Am J Physiol Renal Physiol. 2012;303(8):F1126eF1135.
(12) Morinaga J, Kakizoe Y, Miyoshi T, Onoue T, Ueda M, Mizumoto T, et al. The
antiﬁbrotic effect of a serine protease inhibitor in the kidney. Am J Physiol
Renal Physiol. 2013;305(2):F173eF181.
(13) Narita Y, Ueda M, Uchimura K, Kakizoe Y, Miyasato Y, Mizumoto T, et al.
Combination therapy with renin-angiotensin-aldosterone system inhibitor
telmisartan and serine protease inhibitor camostat mesilate provides further
renoprotection in a rat chronic kidney disease model. J Pharmacol Sci.
2016;130(2):110e116.
(14) Ueda M, Uchimura K, Narita Y, Miyasato Y, Mizumoto T, Morinaga J, et al. The
serine protease inhibitor camostat mesilate attenuates the progression of
chronic kidney disease through its antioxidant effects. Nephron. 2015;129(3):
223e232.
(15) Katunuma N, Le QT, Miyauchi R, Hirose S. Double-layer ﬂuorescent zymog-
raphy for processing protease detection. Anal Biochem. 2005;347(2):
208e212.
(16) Oda T, Jung YO, Kim HS, Cai X, Lopez-Guisa JM, Ikeda Y, et al. PAI-1 deﬁciency
attenuates the ﬁbrogenic response to ureteral obstruction. Kidney Int.
2001;60(2):587e596.
(17) Kakizoe Y, Kitamura K, Ko T, Wakida N, Maekawa A, Miyoshi T, et al. Aberrant
ENaC activation in Dahl salt-sensitive rats. J Hypertens. 2009;27(8):
1679e1689.
Y. Kakizoe et al. / Journal of Pharmacological Sciences 132 (2016) 145e153 153(18) Zhang G, Kernan KA, Collins SJ, Cai X, Lopez-Guisa JM, Degen JL, et al. Plas-
min(ogen) promotes renal interstitial ﬁbrosis by promoting epithelial-to-
mesenchymal transition: role of plasmin-activated signals. J Am Soc Neph-
rol. 2007;18(3):846e859.
(19) Nishiyama A, Yao L, Nagai Y, Miyata K, Yoshizumi M, Kagami S, et al. Possible
contributions of reactive oxygen species and mitogen-activated protein ki-
nase to renal injury in aldosterone/salt-induced hypertensive rats. Hyper-
tension. 2004;43(4):841e848.
(20) Carmeliet P, Schoonjans L, Kieckens L, Ream B, Degen J, Bronson R, et al.
Physiological consequences of loss of plasminogen activator gene function in
mice. Nature. 1994;368(6470):419e424.
(21) Ploplis VA, Carmeliet P, Vazirzadeh S, Van VI, Moons L, Plow EF, et al. Effects of
disruption of the plasminogen gene on thrombosis, growth, and health in
mice. Circulation. 1995;92(9):2585e2593.
(22) Saksela O, Rifkin DB. Cell-associated plasminogen activation: regulation and
physiological functions. Annu Rev Cell Biol. 1988;4:93e126.
(23) Sappino AP, Huarte J, Vassalli JD, Belin D. Sites of synthesis of urokinase and
tissue-type plasminogen activators in the murine kidney. J Clin Invest.
1991;87(3):962e970.
(24) Svenningsen P, Andersen H, Nielsen LH, Jensen BL. Urinary serine proteases
and activation of ENaC in kidney e implications for physiological renal salt
handling and hypertensive disorders with albuminuria. Pﬂugers Arch.
2015;467(3):531e542.
(25) Uchimura K, Kakizoe Y, Onoue T, Hayata M, Morinaga J, Yamazoe R, et al.
In vivo contribution of serine proteases to the proteolytic activation of gam-
maENaC in aldosterone-infused rats. Am J Physiol Renal Physiol. 2012;303(7):
F939eF943.
(26) Kitching AR, Holdsworth SR, Ploplis VA, Plow EF, Collen D, Carmeliet P, et al.
Plasminogen and plasminogen activators protect against renal injury in
crescentic glomerulonephritis. J Exp Med. 1997;185(5):963e968.
(27) Oda T, Yamakami K, Omasu F, Suzuki S, Miura S, Sugisaki T, et al. Glomerular
plasmin-like activity in relation to nephritis-associated plasmin receptor inacute poststreptococcal glomerulonephritis. J Am Soc Nephrol. 2005;16(1):
247e254.
(28) Stetler-Stevenson WG. Dynamics of matrix turnover during pathologic
remodeling of the extracellular matrix. Am J Pathol. 1996;148(5):1345e1350.
(29) Baricos WH, Cortez SL, el-Dahr SS, Schnaper HW. ECM degradation by
cultured human mesangial cells is mediated by a PA/plasmin/MMP-2 cascade.
Kidney Int. 1995;47(4):1039e1047.
(30) Atkinson JM, Pullen N, Johnson TS. An inhibitor of thrombin activated ﬁbri-
nolysis inhibitor (TAFI) can reduce extracellular matrix accumulation in an
in vitro model of glucose induced ECM expansion. Matrix Biol. 2013;32(5):
277e287.
(31) Swaisgood CM, French EL, Noga C, Simon RH, Ploplis VA. The development of
bleomycin-induced pulmonary ﬁbrosis in mice deﬁcient for components of
the ﬁbrinolytic system. Am J Pathol. 2000;157(1):177e187.
(32) Pohl JF, Melin-Aldana H, Sabla G, Degen JL, Bezerra JA. Plasminogen deﬁciency
leads to impaired lobular reorganization and matrix accumulation after
chronic liver injury. Am J Pathol. 2001;159(6):2179e2186.
(33) Edgtton KL, Gow RM, Kelly DJ, Carmeliet P, Kitching AR. Plasmin is not pro-
tective in experimental renal interstitial ﬁbrosis. Kidney Int. 2004;66(1):
68e76.
(34) Moons L, Shi C, Ploplis V, Plow E, Haber E, Collen D, et al. Reduced transplant
arteriosclerosis in plasminogen-deﬁcient mice. J Clin Invest. 1998;102(10):
1788e1797.
(35) Syrovets T, Lunov O, Simmet T. Plasmin as a proinﬂammatory cell activator.
J Leukoc Biol. 2012;92(3):509e519.
(36) Schreiber A, Pham CT, Hu Y, Schneider W, Luft FC, Kettritz R. Neutrophil serine
proteases promote IL-1beta generation and injury in necrotizing crescentic
glomerulonephritis. J Am Soc Nephrol. 2012;23(3):470e482.
(37) Oe Y, Hayashi S, Fushima T, Sato E, Kisu K, Sato H, et al. Coagulation factor Xa
and protease-activated receptor 2 as novel therapeutic targets for diabetic
nephropathy. Arterioscler Thromb Vasc Biol. 2016;36(8):1525e1533.
